Events

Miss Kyra (Jingyi) Gan
Ph.D. Candidate in Operations Research
Carnegie Mellon University

In general, when treatments and effects are observed, but confounders are not, the average treatment effect (ATE) is not identifiable. To estimate the ATE, a practitioner must then either (a) collect deconfounded data; (b) run a clinical trial; or (c) elucidate further properties of the causal graph that might render the ATE identifiable. In this paper, we consider the benefit of incorporating a large confounded observational dataset (confounder unobserved) alongside a small deconfounded observational dataset (confounder revealed) when estimating the ATE. Our theoretical results show that the inclusion of confounded data can significantly reduce the quantity of deconfounded data required to estimate the ATE to within a desired accuracy level. Moreover, in some cases—say, genetics—we could imagine retrospectively selecting samples to deconfound. We demonstrate that by actively selecting these samples based upon the (already observed) treatment and outcome, we can reduce our data dependence further. Our theoretical results establish that the worstcase relative performance of our approach (vs. random selection) is bounded while our best-case gains are unbounded. We perform extensive synthetic experiments to validate our theoretical results. Finally, we demonstrate the practical benefits of selective deconfounding using a large real-world dataset related to genetic mutation in cancer.